Pancreatic Cancer Research

ResearcherErasmus MCActive in the last 2 years

Susan van Dieren

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3084-0495; OpenAlex author ID A5026697149. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
101
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 10 papers

Papers 18

  1. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  2. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  3. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study. Co-author DOI 10.1097/sla.0000000000006021↗
  4. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  5. Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRIN… Co-author DOI 10.1245/s10434-023-14680-0↗
  6. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  7. ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and … Co-author DOI 10.1245/s10434-023-14815-3↗
  8. Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy: A Single-Center Experience. Co-author DOI 10.1245/s10434-024-15591-4↗
  9. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Last author DOI 10.1245/s10434-024-15932-3↗
  10. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… Last author DOI 10.1245/s10434-024-16021-1↗
  11. Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protocol of a multicenter prospective patient p… Co-author DOI 10.1080/0284186x.2023.2273898↗
  12. Intraoperative Ultrasound During Surgical Exploration in Patients with Pancreatic Cancer and Vascular Involvement (ULTRAPANC): A Prospective Multicenter Study. Co-author DOI 10.1245/s10434-023-13112-3↗
  13. Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - a single c… Co-author DOI 10.3389/fonc.2023.1149961↗
  14. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  15. Predictors for Survival in an International Cohort of Patients Undergoing Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08658-5↗
  16. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled t… Co-author DOI 10.1186/s13063-020-4180-z↗
  17. Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ejso.2018.12.003↗
  18. Systematic review of outcomes after distal pancreatectomy with coeliac axis resection for locally advanced pancreatic cancer. Co-author DOI 10.1002/bjs.10148↗

Closest collaborators

The 25 strongest of 101 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 13 shared papers, 2016–2024 · strength 1.82
  2. Thomas F. Stoop · 6 shared papers, 2024 · strength 1.00
  3. Deesje Doppenberg · 5 shared papers, 2023–2024 · strength 0.84
  4. Matthew H. G. Katz · 4 shared papers, 2024 · strength 0.69
  5. Johanna W. Wilmink · 4 shared papers, 2023–2024 · strength 0.63
  6. Bas Groot Koerkamp · 4 shared papers, 2019–2024 · strength 0.62
  7. Rutger T. Theijse · 3 shared papers, 2024 · strength 0.54
  8. Izaak Quintus Molenaar · 3 shared papers, 2024 · strength 0.46
  9. Roeland F. de Wilde · 3 shared papers, 2024 · strength 0.46
  10. Martijn W.J. Stommel · 3 shared papers, 2024 · strength 0.46
  11. Simone Augustinus · 3 shared papers, 2023–2024 · strength 0.45
  12. J. Sven D. Mieog · 3 shared papers, 2023–2024 · strength 0.45
  13. Tobias Keck · 3 shared papers, 2021–2024 · strength 0.41
  14. Amer H. Zureikat · 2 shared papers, 2024 · strength 0.38
  15. Quisette P. Janssen · 2 shared papers, 2024 · strength 0.38
  16. Laura R. Prakash · 2 shared papers, 2024 · strength 0.38
  17. Ching-Wei David Tzeng · 2 shared papers, 2024 · strength 0.38
  18. Alice Chia-Chi Wei · 2 shared papers, 2024 · strength 0.38
  19. Geert Kazemier M · 2 shared papers, 2023–2024 · strength 0.33
  20. Freek D. Daams · 2 shared papers, 2024 · strength 0.31
  21. Sebastiaan Festen · 2 shared papers, 2024 · strength 0.31
  22. Bodil Andersson · 2 shared papers, 2024 · strength 0.31
  23. Karin U. Johansen · 2 shared papers, 2024 · strength 0.31
  24. Michael B. Ghadimi · 2 shared papers, 2024 · strength 0.31
  25. Bergþór Björnsson · 2 shared papers, 2024 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.